The Food and Drug Administration Oct. 13 issued and immediately implemented enforcement policy for modifications to FDA-cleared molecular influenza and RSV tests during the COVID-19 public health emergency to expand access to certain FDA-cleared molecular tests for detecting and identifying flu viruses and respiratory syncytial viruses.

The agency notes that these tests often require the same critical components as many SARS-CoV-2 molecular assays.

Related News Articles

Headline
In a statement (LINK to come) submitted to the Senate Finance Committee for a hearing today on COVID-19 health care flexibilities, AHA urged Congress and…
Headline
The National Academy of Medicine yesterday released separate discussion papers examining the experiences of payers and clinicians during the COVID-19 pandemic…
Headline
COVID-19 vaccination coverage was about 7 percentage points lower in rural counties than in urban counties as of April 10, the Centers for Disease Control and…
Headline
The Federal Emergency Management Agency yesterday released guidance to help emergency managers plan for disaster response and recovery while adhering to…
Headline
Building integrated systems of care can lead to meaningful benefits for patients and help hospitals best serve the health needs of their communities, writes…
Headline
The Food and Drug Administration Friday updated its emergency use authorizations for two intravenous infusion therapies for outpatients at risk for progressing…